Biotechnology companies VectorY Therapeutics and Shape Therapeutics have reached an exclusive license agreement to develop vectorised antibodies for neurodegenerative diseases.  The agreement grants VectorY an exclusive option to evaluate Shape’s deep-brain penetrating adeno-associated virus (AAV) capsid, SHP-DB1, for vectorised antibody payloads against three therapeutic targets. Shape will grant access to its proprietary capsid with VectorY responsible for advancing […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!